脾功能亢进 中国就医指南

Hypersplenism is a hematologic syndrome characterized by splenic overactivity leading to peripheral blood cytopenias—specifically anemia, leukopenia, and/or thrombocytopenia—despite normal or even increased bone marrow production. It is not a standalone disease but rather a functional consequence of underlying pathology affecting the spleen’s filtration, sequestration, and destruction of blood cells. Pathophysiologically, hypersplenism arises from either mechanical (e.g., splenomegaly due to congestion, infiltration, or infection) or immunologic mechanisms (e.g., autoantibody-mediated cell destruction within an enlarged or hyperactive spleen). Common etiologies include chronic liver disease with portal hypertension (e.g., cirrhosis), hematologic malignancies (e.g., lymphoma, myeloproliferative neoplasms), infections (e.g., malaria, kala-azar), storage disorders (e.g., Gaucher disease), and autoimmune conditions (e.g., systemic lupus erythematosus). Epidemiologically, hypersplenism has no precise global incidence but is frequently encountered in tertiary hematology centers—particularly in regions with high prevalence of hepatitis B/C-related cirrhosis, endemic parasitic infections, or inherited metabolic disorders. In China, it is most commonly associated with viral hepatitis–induced portal hypertension and accounts for ~15–20% of cases presenting with unexplained pancytopenia. Risk factors include chronic hepatosplenic disease, prior splenic trauma or infarction, genetic predisposition to hematologic disorders, and immunosuppression. Importantly, hypersplenism must be distinguished from primary bone marrow failure syndromes; diagnosis hinges on demonstrating splenomegaly (via imaging), peripheral cytopenias, and compensatory bone marrow hyperplasia. Untreated, it significantly impairs quality of life: patients experience fatigue, recurrent infections, easy bruising or bleeding, and reduced exercise tolerance. Psychological burden is substantial—especially when diagnostic uncertainty delays intervention or when splenectomy is contemplated. Chronic transfusion dependence may further diminish daily functioning and increase iron overload risk. Early recognition and targeted management of the underlying cause—not just cytopenias—are essential to preserve hematopoietic reserve and prevent complications such as sepsis post-splenectomy or progression of liver disease. Multidisciplinary care involving hematology, hepatology, and interventional radiology optimizes outcomes.

# 脾功能亢进治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用于轻中度血细胞减少、无明显出血或感染、原发病可控制者（如肝硬化代偿期、慢性ITP、淋巴瘤缓解期）：

• •药物治疗：糖皮质激素（泼尼松）、免疫抑制剂（环孢素A、硫唑嘌呤）、促血小板生成素受体激动剂（艾曲泊帕）；

• •支持治疗：输注红细胞/血小板（按单位计）、铁剂、叶酸；

• •基础检查费（初筛+随访）：血常规、外周血涂片、网织红细胞计数、脾脏超声、肝肾功能、凝血四项、骨髓穿刺活检等；

二、手术/介入治疗方案

适用于重度全血细胞减少、反复感染/出血、药物无效或原发病稳定者：

• •腹腔镜脾切除术（金标准）：创伤小、恢复快；

• •脾动脉栓塞术（微创介入）：适用于高龄/手术禁忌者；

• •术前必查：增强CT/MR、心肺功能评估、疫苗接种（肺炎球菌/流感/脑膜炎球菌疫苗），费用1,800–3,200元。

三、特殊复杂情况处理

合并门静脉高压、严重肝衰竭、活动性淋巴瘤或耐药性AIHA者：需多学科协作（血液科+肝病科+介入科）；

• •个体化方案（如联合靶向治疗+分期栓塞+预防性抗生素）；
• •费用区间：65,000–120,000元/周期（含MDT会诊、强化监护、生物制剂等）。

四、方案快速选择指南

• •预算有限/初发轻症：首选药物+支持治疗（年均约2.5–8万元）；
• •中重度/反复并发症：推荐腹腔镜脾切除（性价比最优，根治率＞90%）；
• •高龄/心肺功能差：优先脾动脉栓塞；
• •合并恶性血液病：须先控原发病，再评估脾切时机。